In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Swiss update pandemic hygiene mask standards:

This article was originally published in Clinica

Executive Summary

The proliferation of hygiene masks of varying quality on the market in Switzerland has prompted national regulatory authority Swissmedic to issue a standard practice reminder. Swiss federal health office (BAG) policy is to recommend that the public use hygiene masks in cases of pandemics, Swissmedic told a 30-strong gathering of industry representatives in Bern. Type II and IIR hygiene masks (all of which are subject to CE-marking under the EU's MDD) are its preferred models. They meet the criterion of 98% bacterial filter efficiency (BFE). Manufacturers must conform to EN 14683, said the authority, adding that products already in circulation that do not meet these standards will not be withdrawn, but should be used indoors only. It is difficult to estimate the number of brands available, as Switzerland has "free market" for such products, said Swissmedic.

You may also be interested in...



Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups

Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT049191

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel